GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBMFF) » Definitions » Beta

Sino Biopharmaceutical (Sino Biopharmaceutical) Beta : 0.74 (As of Apr. 30, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Sino Biopharmaceutical Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-04-30), Sino Biopharmaceutical's Beta is 0.74.


Sino Biopharmaceutical Beta Historical Data

The historical data trend for Sino Biopharmaceutical's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Beta Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.06 0.55 0.10 0.32 0.70

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.08 0.32 0.17 0.70

Competitive Comparison of Sino Biopharmaceutical's Beta

For the Biotechnology subindustry, Sino Biopharmaceutical's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Beta distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Beta falls into.



Sino Biopharmaceutical Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Sino Biopharmaceutical  (OTCPK:SBMFF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Sino Biopharmaceutical Beta Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical (Sino Biopharmaceutical) Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (Sino Biopharmaceutical) Headlines

From GuruFocus

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 10-25-2019

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 01-28-2020

GuruFocus Value Idea Contest Sees 2 Winners!

By Holly LaFon Holly LaFon 07-12-2019

Value Idea Contest: Sino Biopharmaceutical

By Matthew Sipos Matthew Sipos 01-10-2019

Matthews China Fund 3rd Quarter Commentary

By Holly LaFon Holly LaFon 10-19-2017

Matthews China Fund Comments on Sino Biopharmaceutical

By Vera Yuan Vera Yuan 10-20-2014